​

SCYNEXIS (SCYX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

SCYX Stock Forecast

SCYNEXIS stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

SCYX Analyst Ratings

Buy

According to 1 Wall Street analysts, SCYNEXIS's rating consensus is 'Buy'. The analyst rating breakdown for SCYX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Mar 01, 2023GuggenheimBuyInitialise

SCYNEXIS's last stock rating was published by Guggenheim on Mar 01, 2023. The company Initialise its SCYX rating from "null" to "Buy".

SCYNEXIS Financial Forecast

SCYNEXIS Revenue Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Mar 21Dec 19Sep 19Jun 19
Revenue-----------------$1.76M$131.45M$1.13M$1.52M$1.56M$1.32M$687.00K$597.00K$516.00K$12.05M--$57.00K
Avg Forecast$42.60M$9.73M$8.98M$8.61M$43.55M$4.62M$4.27M$119.09M$62.12M$6.97M$6.65M$6.36M$7.64M$6.18M$280.00K$240.00K$7.65M$5.89M$95.40M$855.20K$1.15M$2.11M$1.68M$1.09M$1.26M$562.50K$2.50M$20.00K$56.25K$65.60K
High Forecast$53.98M$12.33M$11.38M$10.91M$55.18M$5.86M$5.41M$150.90M$78.72M$8.84M$8.43M$8.06M$9.68M$6.18M$354.79K$304.10K$9.69M$7.47M$120.88M$1.08M$1.45M$2.11M$1.68M$1.09M$1.26M$562.50K$2.50M$20.00K$56.25K$65.60K
Low Forecast$31.22M$7.13M$6.58M$6.31M$31.92M$3.39M$3.13M$87.28M$45.53M$5.11M$4.87M$4.66M$5.60M$6.18M$205.21K$175.90K$5.61M$4.32M$69.92M$626.78K$840.09K$2.11M$1.68M$1.09M$1.26M$562.50K$2.50M$20.00K$56.25K$65.60K
# Analysts111111111111211121111111111131313
Surprise %-----------------0.30%1.38%1.32%1.33%0.74%0.79%0.63%0.47%0.92%4.82%--0.87%

SCYNEXIS's average Quarter revenue forecast for Dec 23 based on 2 analysts is $7.65M, with a low forecast of $5.61M, and a high forecast of $9.69M. SCYX's average Quarter revenue forecast represents a 334.30% increase compared to the company's last Quarter revenue of $1.76M (Sep 23).

SCYNEXIS EBITDA Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Mar 21Dec 19Sep 19Jun 19
# Analysts111111111111211121111111111131313
EBITDA-----------------$-10.10M$115.41M$-10.20M$-22.03M$-21.52M$-21.83M$-19.95M$-22.77M$825.00K$-3.33M$-14.35M$-7.67M$-7.76M
Avg Forecast$-12.57M$-2.87M$-2.65M$-2.54M$-12.85M$-1.36M$-1.26M$-35.15M$-18.34M$-2.06M$-1.96M$-1.88M$-2.26M$-1.82M$-82.64K$-70.83K$-2.26M$-1.74M$-28.16M$-252.40K$-338.30K$-622.62K$-495.36K$-321.70K$-371.63K$-166.01K$-5.21M$-5.90K$-16.60K$-19.36K
High Forecast$-9.22M$-2.10M$-1.94M$-1.86M$-9.42M$-999.76K$-922.76K$-25.76M$-13.44M$-1.51M$-1.44M$-1.38M$-1.65M$-1.82M$-60.56K$-51.91K$-1.65M$-1.27M$-20.64M$-184.98K$-247.94K$-622.62K$-495.36K$-321.70K$-371.63K$-166.01K$-4.17M$-5.90K$-16.60K$-19.36K
Low Forecast$-15.93M$-3.64M$-3.36M$-3.22M$-16.29M$-1.73M$-1.60M$-44.53M$-23.23M$-2.61M$-2.49M$-2.38M$-2.86M$-1.82M$-104.71K$-89.75K$-2.86M$-2.20M$-35.68M$-319.81K$-428.66K$-622.62K$-495.36K$-321.70K$-371.63K$-166.01K$-6.25M$-5.90K$-16.60K$-19.36K
Surprise %-----------------5.81%-4.10%40.41%65.11%34.56%44.07%62.01%61.26%-4.97%0.64%2430.87%461.78%400.72%

1 analysts predict SCYX's average Quarter EBITDA for Sep 23 to be $-1.74M, with a high of $-1.27M and a low of $-2.20M. This is -101.51% lower than SCYNEXIS's previous annual EBITDA (Jun 23) of $115.41M.

SCYNEXIS Net Income Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Mar 21Dec 19Sep 19Jun 19
# Analysts111111111111211121111111111131313
Net Income-----------------$-1.76M$122.26M$-55.62M$-19.13M$-37.18M$-4.81M$-5.45M$-29.24M$-605.00K$-4.68M$-14.46M$-7.94M$-8.40M
Avg Forecast----$29.66M$-7.29M$-6.81M$104.04M$2.43M$972.37K$486.19K$-2.43M$-7.39M$-6.97M$-9.33M$-8.95M$-2.80M$-6.51M$70.59M$-17.02M$-17.38M$-22.80M$-26.49M$-33.67M$-34.69M$-35.17M$-7.30M$-71.15M$-97.02M$-88.13M
High Forecast----$39.96M$-4.76M$-4.44M$140.17M$3.28M$1.31M$655.00K$-1.59M$-4.82M$-4.55M$-6.09M$-5.84M$-1.82M$-4.25M$95.11M$-11.11M$-11.35M$-22.80M$-26.49M$-33.67M$-34.69M$-35.17M$-5.84M$-71.15M$-97.02M$-88.13M
Low Forecast----$19.36M$-9.82M$-9.17M$67.92M$1.59M$634.74K$317.37K$-3.28M$-9.96M$-9.39M$-12.58M$-12.05M$-3.77M$-8.78M$46.08M$-22.93M$-23.42M$-22.80M$-26.49M$-33.67M$-34.69M$-35.17M$-8.76M$-71.15M$-97.02M$-88.13M
Surprise %-----------------0.27%1.73%3.27%1.10%1.63%0.18%0.16%0.84%0.02%0.64%0.20%0.08%0.10%

SCYNEXIS's average Quarter net income forecast for Sep 23 is $-6.51M, with a range of $-8.78M to $-4.25M. SCYX's average Quarter net income forecast represents a -105.33% decrease compared to the company's last Quarter net income of $122.26M (Jun 23).

SCYNEXIS SG&A Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Mar 21Dec 19Sep 19Jun 19
# Analysts111111111111211121111111111131313
SG&A-----------------$5.01M$7.47M$4.84M$15.96M$16.74M$15.79M$14.59M$15.04M$15.41M$6.70M$3.15M$2.48M$2.78M
Avg Forecast$897.31M$204.92M$189.16M$181.28M$917.22M$97.35M$89.85M$2.51B$1.31B$146.91M$140.06M$134.01M$160.96M$130.19M$5.90M$5.05M$161.08M$124.14M$2.01B$18.01M$24.14M$44.43M$35.35M$22.96M$26.52M$11.85M$52.65M$421.21K$1.18M$1.38M
High Forecast$1.14B$259.66M$239.69M$229.70M$1.16B$123.35M$113.85M$3.18B$1.66B$186.14M$177.47M$169.80M$203.95M$130.20M$7.47M$6.40M$204.10M$157.29M$2.55B$22.82M$30.59M$44.43M$35.35M$22.96M$26.52M$11.85M$52.65M$421.21K$1.18M$1.38M
Low Forecast$657.64M$150.19M$138.64M$132.86M$672.23M$71.35M$65.85M$1.84B$958.96M$107.67M$102.65M$98.21M$117.97M$130.19M$4.32M$3.70M$118.06M$90.98M$1.47B$13.20M$17.69M$44.43M$35.35M$22.96M$26.52M$11.85M$52.65M$421.21K$1.18M$1.38M
Surprise %-----------------0.04%0.00%0.27%0.66%0.38%0.45%0.64%0.57%1.30%0.13%7.47%2.09%2.01%

SCYNEXIS's average Quarter SG&A projection for Dec 23 is $161.08M, based on 2 Wall Street analysts, with a range of $118.06M to $204.10M. The forecast indicates a 3112.60% rise compared to SCYX last annual SG&A of $5.01M (Sep 23).

SCYNEXIS EPS Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Mar 21Dec 19Sep 19Jun 19
# Analysts111111111111211121111111111131313
EPS-----------------$-0.04$2.56$-1.16$-0.45$-0.78$-0.11$-0.17$-1.10$-0.02$-0.18$-1.48$-1.40$-1.60
Avg Forecast----$0.61$-0.15$-0.14$2.14$0.05$0.02$0.01$-0.05$-0.15$-0.14$-0.19$-0.18$-0.06$-0.13$1.45$-0.35$-0.36$-0.47$-0.55$-0.69$-0.71$-0.72$-0.59$-1.47$-2.00$-1.82
High Forecast----$0.82$-0.10$-0.09$2.88$0.07$0.03$0.01$-0.03$-0.10$-0.09$-0.13$-0.12$-0.04$-0.09$1.96$-0.23$-0.23$-0.47$-0.55$-0.69$-0.71$-0.72$-0.59$-1.47$-2.00$-1.82
Low Forecast----$0.40$-0.20$-0.19$1.40$0.03$0.01$0.01$-0.07$-0.20$-0.19$-0.26$-0.25$-0.08$-0.18$0.95$-0.47$-0.48$-0.47$-0.55$-0.69$-0.71$-0.72$-0.59$-1.47$-2.00$-1.82
Surprise %-----------------0.27%1.76%3.31%1.26%1.66%0.20%0.24%1.54%0.03%0.31%1.01%0.70%0.88%

According to 1 Wall Street analysts, SCYNEXIS's projected average Quarter EPS for Sep 23 is $-0.13, with a low estimate of $-0.18 and a high estimate of $-0.09. This represents a -105.23% decrease compared to SCYX previous annual EPS of $2.56 (Jun 23).

SCYNEXIS Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
SCYXSCYNEXIS$1.11$8.00620.72%Buy
KMDAKamada$5.75$20.00247.83%
IRWDIronwood Pharmaceuticals$3.53$8.50140.79%Buy
ANIPANI Pharmaceuticals$55.83$79.0041.50%Buy
ORGOOrganogenesis$3.57$5.0040.06%Buy
PCRXPacira BioSciences$19.83$23.7519.77%Hold
LFCRLifecore Biomedical$7.47$6.50-12.99%Buy
PAHCPhibro Animal Health$22.34$18.67-16.43%Buy

SCYX Forecast FAQ

Is SCYNEXIS a good buy?

Yes, according to 1 Wall Street analysts, SCYNEXIS (SCYX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of SCYX's total ratings.

What are SCYNEXIS's analysts' financial forecasts?

SCYNEXIS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $171.52M (high $217.34M, low $125.71M), average EBITDA is $-50.623M (high $-37.102M, low $-64.145M), average net income is $119.6M (high $170.92M, low $68.28M), average SG&A $3.61B (high $4.58B, low $2.65B), and average EPS is $2.46 (high $3.52, low $1.4). SCYX's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $69.92M (high $88.6M, low $51.25M), average EBITDA is $-20.636M (high $-15.124M, low $-26.148M), average net income is $0 (high $0, low $0), average SG&A $1.47B (high $1.87B, low $1.08B), and average EPS is $0 (high $0, low $0).

Did the SCYX's actual financial results beat the analysts' financial forecasts?

Based on SCYNEXIS's last annual report (Dec 2023), the company's revenue was $140.14M, beating the average analysts forecast of $109.8M by 27.63%. Apple's EBITDA was $72.67M, missing the average prediction of $-32.406M by -324.25%. The company's net income was $67.04M, beating the average estimation of $44.27M by 51.45%. Apple's SG&A was $20.92M, missing the average forecast of $2.31B by -99.10%. Lastly, the company's EPS was $0.0014, missing the average prediction of $0.91 by -99.85%. In terms of the last quarterly report (Sep 2023), SCYNEXIS's revenue was $1.76M, missing the average analysts' forecast of $5.89M by -70.12%. The company's EBITDA was $-10.098M, beating the average prediction of $-1.74M by 480.50%. SCYNEXIS's net income was $-1.757M, missing the average estimation of $-6.515M by -73.03%. The company's SG&A was $5.01M, missing the average forecast of $124.14M by -95.96%. Lastly, the company's EPS was $-0.0367, missing the average prediction of $-0.134 by -72.61%